Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free
Autolus Therapeutics NASDAQ AUTL
$4.00 0.0000 0.0000%
Today share price
UK
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 14 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

696.12M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
461.60M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.67
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
174.03M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-37.89 %
Upcoming events Autolus Therapeutics All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Autolus Therapeutics

Stock analysis Autolus Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-3.34 13.17
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
6.24 3.74
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-2.86 9.25
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
1.45 0.06
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-186.93 9.43

Price change Autolus Therapeutics per year

4.60$ 12.79$
Min Max

Summary analysis Autolus Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Autolus Therapeutics

Revenue and net income Autolus Therapeutics

All parameters
Stock news Autolus Therapeutics All news
22 January в 15:30

Autolus Therapeutics Gets BLA Acceptance for Obecabtagene Autoleucel

22 January в 15:25

Autolus Therapeutics Gets BLA Acceptance for Obecabtagene Autoleucel

2 June 2023 в 14:25

Autolus Therapeutics Sees Positive Data in Obe-Cel Trial

2 June 2023 в 14:25

Autolus Therapeutics Sees Positive Data in Obe-Cel Trial

8 March 2023 в 17:20

Autolus Therapeutics stock price target cut to $12 from $18 at Mizuho

9 December 2022 в 22:00

Autolus Therapeutics ADSs Sink to New Depths After Dilutive Offering >AUTL

9 December 2022 в 21:55

Autolus Therapeutics ADSs Sink to New Depths After Dilutive Offering >AUTL

9 December 2022 в 14:10

Autolus Therapeutics ADSs Tumble Premarket on Public Offering >AUTL

9 December 2022 в 14:10

Autolus Therapeutics ADSs Tumble Premarket on Public Offering >AUTL

12 October 2022 в 19:52

Autolus Therapeutics Shares Rise 16% After Moderna Exercises Licensing Option

12 October 2022 в 19:52

Autolus Therapeutics Shares Rise 16% After Moderna Exercises Licensing Option

4 October 2022 в 14:51

Autolus Therapeutics Shares Jump After Cancer-Collaboration Agreement with Bristol Myers

4 October 2022 в 14:51

Autolus Therapeutics Shares Jump After Cancer-Collaboration Agreement with Bristol Myers

9 November 2021 в 19:25

PE Daily: Collibra Hits $5.25 Billion Valuation | Carlyle Vet Quarles to Leave the Fed | Blackstone Backs Autolus Therapeutics

8 November 2021 в 20:20

Autolus Therapeutics ADRs Up After Deal for Blackstone Investment

8 November 2021 в 20:15

Autolus Therapeutics ADRs Up After Deal for Blackstone Investment

8 November 2021 в 05:05

Blackstone to Invest Up to $250 Million in Autolus Therapeutics

About company Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
Address:
Forest House, London, United Kingdom, W12 7RZ
Company name: Autolus Therapeutics
Issuer ticker: AUTL
ISIN: US05280R1005
Country: UK
Exchange: NASDAQ
Currency: $
IPO date: 2018-06-22
Sector: Healthcare
Industry: Biotechnology
Site: https://www.autolus.com

On which stock exchange are Autolus Therapeutics (AUTL) stocks traded?

Autolus Therapeutics (AUTL) stocks are traded on NASDAQ.

What is the ticker of Autolus Therapeutics stocks (AUTL)?

The stock ticker of Autolus Therapeutics’s stocks or in other words, the code is AUTL. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Autolus Therapeutics (AUTL) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Autolus Therapeutics (AUTL) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Autolus Therapeutics (AUTL) stocks traded?

Autolus Therapeutics (AUTL) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Autolus Therapeutics (AUTL) stocks today?

The current price of Autolus Therapeutics stocks on 29.04.2024 is 4 dollars. per share.

What is the dynamics of Autolus Therapeutics (AUTL) stocks from the beginning of the year?

Autolus Therapeutics (AUTL) quotes have increased by -41.52% from the beginning of the year up to 4 dollars. per 1 stocks.

How much did Autolus Therapeutics (AUTL) stocks increase in апреле 2024?

This month Autolus Therapeutics (AUTL) quotes have increased by -29.58% to 4 dollars. per share.

How much are Autolus Therapeutics (AUTL) stocks worth?

Today, on October, 29.04.2024 Autolus Therapeutics’s (AUTL) stocks cost 4 dollars..

What is the market capitalization of Autolus Therapeutics (AUTL)?

Capitalization is the market value of Autolus Therapeutics (AUTL) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 29.04.2024, the market capitalization of Autolus Therapeutics (AUTL) is estimated at about 696116604 dollars.